Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0E0AA
|
|||
Former ID |
DNC010916
|
|||
Drug Name |
N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX)
|
|||
Synonyms |
CHEMBL1085261; N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX); SCHEMBL1404507; BDBM50320173
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C24H22Cl2N2O3
|
|||
Canonical SMILES |
CC1(CC(C2=C(O1)N=C(C(=C2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4Cl)NC(=O)CO)C
|
|||
InChI |
1S/C24H22Cl2N2O3/c1-24(2)12-20(27-21(30)13-29)18-11-17(14-7-9-15(25)10-8-14)22(28-23(18)31-24)16-5-3-4-6-19(16)26/h3-11,20,29H,12-13H2,1-2H3,(H,27,30)
|
|||
InChIKey |
XFJREZUFRMFGKX-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [1] |
Cannabinoid receptor 2 (CB2) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Rap1 signaling pathway | ||||
Retrograde endocannabinoid signaling | ||||
Panther Pathway | Endogenous cannabinoid signaling | |||
Pathway Interaction Database | N-cadherin signaling events | |||
Reactome | Class A/1 (Rhodopsin-like receptors) | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Small Ligand GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
BDNF signaling pathway | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.